XML 22 R12.htm IDEA: XBRL DOCUMENT

Contingent Earn-Out Consideration

3 Months Ended

Mar. 31, 2023

NOTE 5. CONTINGENT EARN-OUT CONSIDERATION

The following table provides a reconciliation of our Level 3 earn-out liabilities for the three months ended March 31, 2023:


Balance, December 31, 2022	$	3,640
Change in fair value of earn-out liabilities		80
Balance, March 31, 2023	$	3,720

The current portion of contingent earn-out liabilities is included in Other-current liabilities and the non-current portion is included in Other long-term liabilities on the Condensed Consolidated Balance Sheet. As of March 31, 2023, the current portion was $3,460 and the non-current portion was $260. During the three months ended March 31, 2023, we reassessed the estimate of the earn-out liabilities which resulted in a net increase of $80 recorded in Other expense within the Condensed Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31, 2023. One of the milestones associated with the Additive Orthopaedics acquisition and included in Accrued expenses as of December 31, 2022 was paid in cash during the three months ended March 31, 2023. Three project milestones associated with the Disior acquisition, totaling $5,000 and completed during 2022 remain included in Accrued expenses on the Condensed Consolidated Balance Sheet as of March 31, 2023. For additional information on the Additive Orthopaedics acquisition refer to Note 3 to our Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.